SCHEMBL5386491

SCHEMBL5386491

CC1C(=O)c2ccc([N+](=O)[O-])cc2N1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASP1 P29466 1/20 0.48
▸ CASP3 P42574 1/20 0.48
▸ CASP4 P49662 1/20 0.48
▸ CASP7 P55210 1/20 0.48
▸ CASP9 P55211 1/20 0.48
▸ CASP6 P55212 1/20 0.48
▸ ALDH1A1 P00352 5/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ PTPRC P08575 3/20 0.46
▸ S100A4 P26447 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ NR1H2 P55055 1/20 0.45
▸ NR1H3 Q13133 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ TDP1 Q9NUW8 3/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ ACHE P22303 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27719428 0.88 CASP1 (0.55) CASP1CASP3CASP4CASP7CASP9
SCHEMBL6537456 0.72 ALDH1A1 (0.60) CASP1CASP3CASP4CASP7CASP9
SCHEMBL30513055 0.72 NR1H2 (0.51) CASP1CASP3CASP4CASP7CASP9
SCHEMBL26621563 0.71 CASP3 (0.77) CASP1CASP3CASP4CASP7CASP9
SCHEMBL27690180 0.71 CYP1A2 (0.43) CASP1CASP3CASP4CASP7CASP9
SCHEMBL31419431 0.69 CASP3 (0.72) CASP1CASP3CASP4CASP7CASP9
SCHEMBL28852929 0.69 ALDH1A1 (0.44) CASP1CASP3CASP4CASP7CASP9
SCHEMBL9066778 0.69 L3MBTL1 (0.46) CASP1CASP3CASP4CASP7CASP9
SCHEMBL4611589 0.69 ALDH1A1 (0.50) CASP1CASP3CASP4CASP7CASP9
SCHEMBL2061938 0.69 CASP1 (0.51) CASP1CASP3CASP4CASP7CASP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312330-B2 Bicycloheteroarylamine compounds as ion channel ligands and uses thereof RENOVIS, INC. (US) 2007-12-25 — — US disclosed
WO-2006118598-A1 BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF RENOVIS, INC. (US) 2006-11-09 — — WO disclosed
US-20050277643-A1 Bicycloheteroarylamine compounds as ion channel ligands and uses thereof EVOTEC AG (DE) 2005-12-15 — — US disclosed
CN-85103724-B Process for preparing pyrrolobenzimidazoles 曼海姆伯灵格股份公司 1988-07-06 — — CN disclosed
CN-85103724-A The method for preparing novel pyrrolo-benzoglyoxaline — 1986-07-02 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277643-A1 Bicycloheteroarylamine compounds as ion channel ligands and uses thereof TRPV1, TRPV3, TRPA1 CASP1 551/4885CASP3 748/4885CASP4 781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback